Activity

Filter

Cancel
Date Panel Item Activity
10 actions
Mendeliome v1.1016 SLC4A3 Zornitza Stark Publications for gene: SLC4A3 were set to PMID: 29167417; 34557911
Mendeliome v1.1015 SLC4A3 Zornitza Stark Classified gene: SLC4A3 as Green List (high evidence)
Mendeliome v1.1015 SLC4A3 Zornitza Stark Gene: slc4a3 has been classified as Green List (High Evidence).
Mendeliome v1.972 SLC4A3 Chern Lim reviewed gene: SLC4A3: Rating: GREEN; Mode of pathogenicity: None; Publications: 36806574; Phenotypes: Short QT syndrome 7, MIM#620231; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted; Current diagnostic: yes
Mendeliome v1.620 SLC4A3 Zornitza Stark Phenotypes for gene: SLC4A3 were changed from Short QT syndrome to Short QT syndrome 7, MIM#620231
Mendeliome v0.9556 SLC4A3 Zornitza Stark Marked gene: SLC4A3 as ready
Mendeliome v0.9556 SLC4A3 Zornitza Stark Gene: slc4a3 has been classified as Amber List (Moderate Evidence).
Mendeliome v0.9556 SLC4A3 Zornitza Stark Classified gene: SLC4A3 as Amber List (moderate evidence)
Mendeliome v0.9556 SLC4A3 Zornitza Stark Gene: slc4a3 has been classified as Amber List (Moderate Evidence).
Mendeliome v0.9355 SLC4A3 Daniel Flanagan gene: SLC4A3 was added
gene: SLC4A3 was added to Mendeliome. Sources: Expert Review
Mode of inheritance for gene: SLC4A3 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Publications for gene: SLC4A3 were set to PMID: 29167417; 34557911
Phenotypes for gene: SLC4A3 were set to Short QT syndrome
Review for gene: SLC4A3 was set to AMBER
Added comment: Moderate evidence for autosomal dominant short QT syndrome 1 by ClinGen /gene curation expert panel (PMID: 34557911). A single missense variant (absent gnomAD) identified in two SQTS families. In family 1, it segregated with SQTS (QTc<370ms) in 23 carriers, and 19 non-carriers had a QTc>370ms. In family 2, it segregated in 4 individuals. Experimental evidence from in vitro and zebrafish models suggests reduced membrane localization of the mutated protein leads to intracellular alkalinization and shortening of the cardiomyocyte action potential duration.
ClinGen expert panel was divided between strong (4 votes) and moderate (5 votes).
Sources: Expert Review